Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/36863
Title: Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects
Authors: Podjanee Jittamala
Sasithon Pukrittayakamee
Elizabeth A. Ashley
François Nosten
Borimas Hanboonkunupakarn
Sue J. Lee
Praiya Thana
Kalayanee Chairat
Daniel Blessborn
Salwaluk Panapipat
Nicholas J. White
Nicholas P.J. Day
Joel Tarningb
Mahidol University
Nuffield Department of Clinical Medicine
Keywords: Medicine
Issue Date: 1-Jan-2015
Citation: Antimicrobial Agents and Chemotherapy. Vol.59, No.1 (2015), 505-513
Abstract: © 2015 Jittamala et al. Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs. Seventeen healthy adults received a single oral dose of primaquine alone (30 mg base) and were then randomized to receive pyronaridine-artesunate alone (540-180 mg) or pyronaridineartesunate plus primaquine in combination, with intervening washout periods between all treatments. The pharmacokinetic properties of primaquine, its metabolite carboxyprimaquine, artesunate, its metabolite dihydroartemisinin, and pyronaridine were assessed in 15 subjects using a noncompartmental approach followed by a bioequivalence evaluation. All drugs were well tolerated. The single oral dose of primaquine did not result in any clinically relevant pharmacokinetic alterations to pyronaridine, artesunate, or dihydroartemisinin exposures. There were significantly higher primaquine maximum plasma drug concentrations (geometric mean ratio, 30%; 90% confidence interval [CI], 17% to 46%) and total exposures (15%; 6.4% to 24%) during coadministration with pyronaridine-artesunate than when primaquine was given alone. Pyronaridine, like chloroquine and piperaquine, increases plasma primaquine concentrations. (This study has been registered at ClinicalTrials.gov under registration no. NCT01552330.)
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84920179913&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/36863
ISSN: 10986596
00664804
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.